Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial
Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial
复制标题
DOI：
10.1016/j.jff.2018.05.018
复制
发表时间：
2018-07-01
影响因子：
5.6
通讯作者：
Mafra, Denise
中科院分区：
文献类型：
--
作者：
Banos, Amanda de Faria;Borges, Natalia A.;Mafra, Denise
益生菌可以减轻尿毒症毒素和炎症生物标志物的产生。本研究的目的是评估益生菌对慢性肾脏病尿毒症毒素和炎症生物标志物的影响。在这项随机、双盲、安慰剂对照试验中，（63.8 ± 7.5岁，14名男性，平均BMI为27.2 ± 3.8 kg/m2）被分配接受两种治疗之一：益生菌（n = 15;嗜热链球菌、嗜酸乳杆菌和长双歧杆菌-每天900亿CFU）或安慰剂（n = 15），持续三个月。使用反相液相色谱法（RP-HPLC）测量血浆尿毒症毒素;使用液相色谱-质谱法（LC-MS/MS）测量胆碱、甜菜碱和三甲胺-N-氧化物（TMAO）;使用ELISA测量炎症生物标志物。尿毒症毒素不受益生菌的影响;然而，IL-6水平从15.6（14.8-20.8）pg/mL显著增加至23.0（17.6-29.6）pg/mL，p = 0.01。基线时，对甲苯基硫酸盐和尿素（r = 0.55; p = 0.02）以及TMAO和CRP（r = 0.46; p = 0.05）水平之间呈正相关。这些数据表明，益生菌补充剂没有为非透析CKD患者带来预期的益处。
Probiotics may mitigate the generation of uremic toxins and inflammatory biomarkers. The aim of this study was to evaluate the effects of probiotics on uremic toxins and inflammatory biomarkers in CKD. In this randomized, double-blind, placebo-controlled trial, 30 patients (63.8 +/- 7.5 years, 14 men, mean BMI of 27.2 +/- 3.8 kg/m(2)) were assigned to receive one of two treatments: probiotics (n = 15; Streptococcus thermophilus, Lactobacillus acidophilus and Bifidobacteria longum-90 billion CFU per day) or placebo (n = 15) daily for three months. Plasma uremic toxins were measured using reversed-phase liquid-chromatography (RP-HPLC); choline, betaine and trimethylamine-N-oxide (TMAO) were measured using liquid chromatography-mass spectrometry (LC-MS/MS); and inflammatory biomarkers were measured using ELISA. Uremic toxins were not influenced by the probiotics; however, IL-6 levels increased significantly from 15.6 (14.8-20.8) pg/mL to 23.0 (17.6-29.6) pg/mL, p = 0.01. There was a positive correlation between the levels of p-cresyl sulfate and urea (r = 0.55; p = 0.02) and between TMAO and CRP (r = 0.46; p = 0.05) at baseline. These data suggest that probiotic supplementation did not result in expected benefits for non-dialysis CKD patients.